List of Excipients in Branded Drug TAUVID

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	TAUVID	flortaucipir f-18	0002-1210	ALCOHOL	2032-05-26
Eli Lilly and Company	TAUVID	flortaucipir f-18	0002-1210	SODIUM CHLORIDE	2032-05-26
Eli Lilly and Company	TAUVID	flortaucipir f-18	0002-1220	ALCOHOL	2032-05-26
Eli Lilly and Company	TAUVID	flortaucipir f-18	0002-1220	CYSTEINE HYDROCHLORIDE	2032-05-26
Eli Lilly and Company	TAUVID	flortaucipir f-18	0002-1220	HYDROCHLORIC ACID	2032-05-26
Eli Lilly and Company	TAUVID	flortaucipir f-18	0002-1220	SODIUM CHLORIDE	2032-05-26

TAUVID Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

TAUVID, Eli Lilly’s flortaucipir F 18 injection, is a short-lived PET diagnostic with limited formulation latitude and a highly specialized supply chain. The commercial opportunity is concentrated in manufacturing reliability, radiopharmacy automation, excipient quality, regional production, and clinical workflow integration rather than in conventional reformulation or generic substitution.

TAUVID is administered intravenously at approximately 370 MBq, or 10 mCi, and is used for PET imaging of aggregated tau neurofibrillary tangles in adults being evaluated for Alzheimer’s disease. Fluorine-18 has a physical half-life of approximately 110 minutes, making local production, rapid release testing, and controlled distribution central to the product’s economics.[1]

What is TAUVID and how does its formulation work?

TAUVID contains flortaucipir F 18, a radiolabeled small-molecule imaging agent. The product is supplied as a sterile, nonpyrogenic intravenous injection for single use.

The commercial formulation uses a conventional aqueous vehicle rather than a complex sustained-release, lipid, polymer, or biologic delivery system. Public labeling identifies sodium chloride, ethanol, and water for injection as formulation components.[1,2]

Product attribute	TAUVID profile
Active ingredient	Flortaucipir F 18
Therapeutic category	Diagnostic radiopharmaceutical
Imaging modality	Positron emission tomography
Route	Intravenous injection
Standard administered activity	Approximately 370 MBq, or 10 mCi
Imaging timing	Approximately 80 minutes after administration
Scan duration	Approximately 20 minutes
Radionuclide half-life	Approximately 109.8 minutes
Formulation type	Sterile aqueous injection
Key excipients identified in labeling	Sodium chloride, ethanol, water for injection
Sponsor	Eli Lilly through Avid Radiopharmaceuticals
FDA approval	May 28, 2020

The excipient system has four practical functions:

1. It provides an isotonic injectable vehicle.
2. It supports solubilization and handling of the tracer.
3. It maintains chemical and radiochemical quality during the short distribution period.
4. It supports sterile production and administration in hospital or commercial radiopharmacy settings.

The formulation is not designed to extend systemic exposure. Its purpose is to deliver a reproducible bolus of radiolabeled tracer before radioactive decay materially reduces available activity.

What excipients are used in TAUVID?

The publicly identified excipients are sodium chloride, ethanol, and water for injection.[1,2]

Sodium chloride

Sodium chloride provides tonicity and supports intravenous tolerability. Its principal commercial value is supply consistency and injectable-grade quality rather than differentiation. Suppliers must meet applicable compendial, sterility, endotoxin, particulate, and elemental impurity specifications.

Ethanol

Ethanol can support solubilization of the lipophilic flortaucipir molecule and may assist formulation and manufacturing control. Its concentration must remain compatible with intravenous administration, container closure materials, radiochemical stability, and the product’s toxicology profile.

Ethanol is commercially relevant because changes in concentration can affect:

• Solubility and precipitation risk
• Radiochemical purity
• Adsorption to vials, syringes, and tubing
• Residual solvent exposure
• Automated dispensing performance
• Stability during the short shelf life

Water for injection

Water for injection is the primary vehicle. It must meet applicable requirements for sterility, endotoxins, particulate matter, and chemical quality.

For radiopharmaceutical production, water quality controls also interact with radionuclide chemistry. Trace metals, oxidants, and ionic contaminants can reduce labeling efficiency or increase radiochemical impurities.

What excipient strategy is commercially relevant for TAUVID?

The highest-value strategy is controlled simplification. TAUVID does not require a large excipient platform. Its commercial advantage depends on maintaining a narrow, validated formulation while improving manufacturing and distribution execution.

High-value excipient opportunities

Opportunity	Commercial value	Technical constraint
Radiopharmaceutical-grade water supply	High	Must support sterile, low-endotoxin production
Injectable ethanol sourcing	Moderate	Concentration and residual solvent control
Sodium chloride supply	Low to moderate	Compendial consistency and sterile processing
Low-adsorption container closure systems	Moderate	Must preserve delivered activity and concentration
Automated dispensing components	High	Must minimize dead volume and radiation exposure
Single-use sterile fluid paths	High	Compatibility with ethanol and radionuclide processing
Regional sterile compounding services	High	Requires validated production and rapid release
Radiochemical quality-control systems	High	Supports release within the short half-life
Shelf-life and transport optimization	High	Must account for radioactive decay and time zones

The best commercial opportunities are therefore adjacent to the excipient system. A supplier that provides validated sterile fluid paths, low-binding syringes, automated dose dispensers, or radiopharmaceutical-compatible container closures may capture more value than a supplier offering a new inactive ingredient.

What formulations are protected by TAUVID-related intellectual property?

TAUVID’s commercial protection is likely to depend more on flortaucipir composition, radiolabeling chemistry, imaging methods, manufacturing processes, and regulatory exclusivity than on the basic sodium chloride, ethanol, and water vehicle.

A conventional aqueous formulation with broadly used injectable excipients is difficult to protect as a standalone commercial moat unless claims include specific concentration ranges, stability characteristics, radiochemical purity, container systems, or manufacturing conditions.

Potential formulation claim areas

Relevant intellectual-property categories can include:

• Flortaucipir chemical structure
• Fluorine-18 labeling methods
• Precursor compounds and radiochemical synthesis
• Purification and quality-control processes
• Specific solvent or excipient ratios
• Stability during synthesis, transport, or administration
• Low-adsorption or dose-delivery systems
• Imaging methods using flortaucipir
• Patient-selection or diagnostic interpretation methods

The practical strength of an excipient patent would depend on whether a competitor could use a different solvent system, concentration, vessel, or synthesis process while preserving equivalent clinical performance.

When does TAUVID lose FDA exclusivity?

TAUVID received FDA approval on May 28, 2020.[1] A five-year new chemical entity exclusivity period would generally run through May 28, 2025, subject to the specific FDA Orange Book designation and any applicable pediatric or patent-related provisions.[3]

Milestone	Date or status
FDA approval	May 28, 2020
Five-year NCE exclusivity, if applicable	Approximately May 28, 2025
Radiopharmaceutical half-life	Approximately 110 minutes
Current commercial issue	Local production and operational access, not only legal exclusivity

Loss of regulatory exclusivity does not create an immediate conventional generic market. An entrant must reproduce the active radiolabeled product, demonstrate pharmaceutical equivalence, satisfy radiopharmaceutical manufacturing requirements, and operate within the short F-18 distribution window.

What is the Orange Book status of TAUVID?

The FDA Orange Book is the principal source for approved drug-product patents and exclusivity information.[3] TAUVID’s relevant regulatory protection should be evaluated through its product entry, patent-listing records, exclusivity codes, and any later supplements.

For a radiopharmaceutical, Orange Book analysis has limits. Product-level competition may arise through:

• An abbreviated new drug application
• A 505(b)(2) application
• A separately manufactured flortaucipir F 18 product
• A different formulation with the same diagnostic purpose
• A competing tau PET tracer

A substitute tau tracer may avoid direct Orange Book infringement while competing for the same imaging procedure and reimbursement channel.

How many patents cover TAUVID?

The relevant patent estate should be divided into five groups rather than counted as a single formulation portfolio:

1. Flortaucipir molecule patents
2. Radiolabeling and precursor patents
3. Diagnostic imaging method patents
4. Formulation and container patents
5. Manufacturing, purification, and quality-control patents

The basic excipient combination is unlikely to provide the principal exclusivity barrier. The stronger commercial barriers are expected to be technical and operational: validated production, precursor availability, radiochemical release testing, regulatory history, and access to PET imaging centers.

Patent strength should be assessed using claim scope, expiration, terminal disclaimers, patent-term adjustment, prosecution history, and design-around options. A broad composition-of-matter claim can materially restrict competition. A narrow claim directed to ethanol concentration or a particular container configuration is easier to design around.

Are there Paragraph IV challenges to TAUVID?

A Paragraph IV challenge would require an ANDA applicant to assert that relevant listed patents are invalid, unenforceable, or not infringed. The commercial probability of such a filing is lower than for a conventional oral drug because the entrant must also establish a viable radiopharmacy manufacturing and distribution network.

Challenge factor	Effect on TAUVID
Short F-18 half-life	Raises manufacturing and logistics costs
Limited number of PET sites	Concentrates demand but limits reachable volume
Complex radiochemical synthesis	Increases technical entry barriers
Aqueous formulation	Makes excipient design-around relatively feasible
Diagnostic reimbursement	May limit commercial return
Competing tau and amyloid tracers	Reduces dependence on one product
Local cyclotron requirement	Favors regional or site-based production

A Paragraph IV filing would be more commercially credible if the applicant already had radiopharmaceutical infrastructure, cyclotron access, automated synthesis equipment, and an established nuclear medicine sales network.

What generic launch scenarios exist for TAUVID?

Scenario 1: Regional radiopharmacy launch

A competitor manufactures flortaucipir F 18 near major PET centers. This model reduces decay-related losses and limits reliance on national distribution. It is the most operationally credible generic scenario.

Scenario 2: 505(b)(2) or differentiated formulation

An entrant uses a modified vehicle, container system, or manufacturing process. The product may seek a regulatory pathway that relies partly on existing safety and clinical information while establishing formulation-specific data.

Scenario 3: Institutional compounding or outsourcing

Hospitals or outsourcing facilities produce the tracer for internal or regional use, subject to applicable FDA, state, and nuclear pharmacy requirements. This approach may reduce branded-product dependence but introduces consistency, validation, and liability issues.

Scenario 4: Clinical substitution

Providers use Amyvid, Vizamyl, Neuraceq, or another tau-directed agent when clinically appropriate. This is not generic entry, but it is a direct commercial risk to TAUVID utilization.

Which companies are challenging TAUVID commercially?

TAUVID competes within two related markets:

• Tau PET imaging
• Alzheimer’s disease biomarker imaging more broadly

Amyvid, Vizamyl, and Neuraceq are established amyloid PET agents. They do not provide the same tau endpoint, but they compete for PET scanner capacity, nuclear medicine budgets, prescriber attention, and diagnostic reimbursement.

Tau PET competition may also arise from investigational or regionally approved tracers. Commercial substitution depends on tracer availability, diagnostic performance, interpretation standards, reimbursement, and physician preference.

Product	Target	Company association	Commercial relationship to TAUVID
TAUVID	Tau neurofibrillary tangles	Eli Lilly/Avid	Direct tau PET reference product
Amyvid	Amyloid plaques	Eli Lilly	Indirect portfolio and workflow competitor
Vizamyl	Amyloid plaques	GE HealthCare	Competes for PET capacity and Alzheimer’s imaging
Neuraceq	Amyloid plaques	Life Molecular Imaging	Competes for imaging budgets and site access

How strong is the TAUVID patent estate?

The estate is strongest where it controls the tracer molecule, radiolabeling process, or validated diagnostic use. It is weaker where protection depends only on common injectable excipients.

A commercial strength assessment should score the portfolio across four dimensions:

Dimension	Assessment
Composition-of-matter protection	Potentially strong if unexpired and broadly claimed
Formulation protection	Likely narrower because the vehicle uses conventional excipients
Manufacturing protection	Potentially significant because radiochemical synthesis is specialized
Method-of-use protection	Relevant but vulnerable to clinical and legal design-around strategies

The operational moat may outlast or outweigh formulation patent protection. A competitor needs reliable precursor supply, cyclotron production, synthesis equipment, validated quality systems, trained personnel, and access to imaging sites.

What manufacturing and IP barriers affect TAUVID?

TAUVID production requires rapid synthesis and release of a radioactive product. The key manufacturing barriers include:

• F-18 production through a cyclotron
• Precursor and reagent qualification
• Automated radiochemistry equipment
• Sterile filtration and aseptic processing
• Radiochemical identity and purity testing
• Radionuclide identity and activity measurement
• Endotoxin and sterility controls
• Container closure compatibility
• Time-critical release and delivery
• Radiation safety and licensed operations

Excipient changes can affect each stage. Ethanol concentration can alter solubility and adsorption. Water quality can affect radiochemical synthesis. Sodium chloride concentration can affect tonicity and final product control. Container materials can alter recovery of a low-dose, short-lived tracer.

What licensing deals affect TAUVID?

TAUVID was developed by Avid Radiopharmaceuticals, which Eli Lilly acquired in 2010. The product is commercialized within Lilly’s radiopharmaceutical and neuroscience portfolio.[4]

The principal licensing opportunity is not likely to be a simple excipient license. More attractive structures include:

• Regional manufacturing rights
• Cyclotron-network supply agreements
• Automated synthesis platform partnerships
• Contract radiopharmacy production
• Precursor supply agreements
• PET center distribution contracts
• Companion diagnostic or biomarker collaborations
• Data and interpretation software partnerships

A regional manufacturing agreement can have greater commercial value than an excipient license because geographic production reduces decay losses and improves dose availability.

What is the FDA regulatory status of TAUVID?

TAUVID is FDA-approved for PET imaging of aggregated tau neurofibrillary tangles in adults being evaluated for Alzheimer’s disease.[1] The label also contains important limitations concerning interpretation and the relationship between tracer uptake and clinical diagnosis.

Any reformulated product would require evidence addressing:

• Pharmaceutical equivalence
• Radiochemical purity
• Delivered activity
• Biodistribution
• Brain uptake and washout
• Image quality
• Specificity and sensitivity
• Sterility and endotoxin control
• Container closure performance
• Stability through administration

A new excipient is not commercially attractive if it requires extensive bridging studies without improving shelf life, site availability, production yield, or delivery reliability.

What is the revenue exposure from TAUVID?

Eli Lilly reports product and business performance at the corporate and portfolio level, but TAUVID revenue is not consistently disclosed as a separately material line item in public financial reporting.[4] Revenue exposure is therefore best analyzed through utilization drivers:

• Number of PET-capable sites
• Annual Alzheimer’s diagnostic volume
• Reimbursement rates
• Tracer availability
• Cyclotron density
• Dose wastage from decay
• Interpretation capacity
• Competition from amyloid imaging
• Adoption of disease-modifying Alzheimer’s therapies

The strongest commercial upside comes from increased biomarker testing tied to treatment eligibility and disease monitoring. The main constraint is that TAUVID requires specialized PET infrastructure and does not function as a routine retail prescription product.

What geographic markets offer the strongest commercial opportunities?

The United States has the clearest regulatory and commercial reference market because TAUVID has FDA approval and an established reimbursement framework. Europe, Japan, and other markets may offer opportunities through local regulatory approvals, regional cyclotron networks, and hospital-based radiopharmacy production.

Geographic expansion depends on:

• Local approval of flortaucipir F 18
• Availability of F-18 production
• Nuclear medicine licensing
• PET scanner density
• Alzheimer’s diagnostic guidelines
• Reimbursement for tau imaging
• Local manufacturing or import feasibility

The preferred supply model is regional. National shipment is less efficient as transport time consumes a substantial portion of the radionuclide’s usable activity.

Key Takeaways

• TAUVID uses a simple aqueous formulation containing sodium chloride, ethanol, and water for injection.
• The excipient system is unlikely to be the primary commercial moat.
• The strongest opportunities are in sterile components, automated dispensing, radiopharmacy production, quality control, and regional distribution.
• F-18’s approximately 110-minute half-life makes local manufacturing and logistics more important than conventional shelf-life extension.
• FDA approval occurred on May 28, 2020, with five-year NCE exclusivity generally expected to end around May 28, 2025, subject to the specific Orange Book record.
• Generic entry would require more than formulation replication. It would require validated radiochemical manufacturing, cyclotron access, licensed operations, and PET-site distribution.
• Amyloid PET agents compete for imaging capacity and diagnostic budgets, even though they target a different pathology.
• A new excipient is commercially attractive only if it improves radiochemical stability, dose recovery, manufacturing yield, or site-level usability without creating a large regulatory burden.

FAQs

Can TAUVID be reformulated with a different alcohol or cosolvent?

A different cosolvent could be technically feasible, but it would require evaluation of solubility, radiochemical purity, intravenous tolerability, adsorption, container compatibility, and regulatory comparability. The short product lifetime limits the value of conventional long-term stability improvements.

Is TAUVID suitable for a conventional generic drug strategy?

No. A viable competitor would need radiopharmaceutical manufacturing and regional distribution capabilities. The business model resembles a distributed nuclear medicine supply network more than a conventional tablet generic.

Which excipient has the greatest strategic importance in TAUVID?

Ethanol has the greatest formulation significance because it can affect solubility, adsorption, residual solvent exposure, and radiochemical performance. Water for injection and sodium chloride remain critical for quality and tolerability but offer less differentiation.

Could a low-adsorption syringe create a commercial advantage?

Yes. A validated syringe or administration set that improves dose recovery, reduces tracer loss, and supports automated dispensing could create operational value without changing the approved formulation. The product would still require compatibility and performance validation.

Does TAUVID have biosimilar risk?

No. Biosimilar pathways apply to biological products. TAUVID is a radiolabeled small-molecule diagnostic. Its relevant competitive risks are generic, 505(b)(2), institutional production, and alternative PET tracers.

References

1. U.S. Food and Drug Administration. (2020). TAUVID (flortaucipir F 18 injection) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212123s000lbl.pdf

2. National Library of Medicine. (n.d.). DailyMed: TAUVID- flortaucipir F 18 injection. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. Eli Lilly and Company. (2024). Annual report. https://investor.lilly.com/financial-information/annual-reports-and-proxy-statements